Stealth BioTherapeutics (NASDAQ:MITO) Rating Reiterated by HC Wainwright

Stealth BioTherapeutics (NASDAQ:MITO)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued on Friday, reports. They presently have a $30.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 156.41% from the company’s previous close.

Separately, Zacks Investment Research downgraded HEXO from a “hold” rating to a “sell” rating in a report on Wednesday, May 15th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Stealth BioTherapeutics presently has a consensus rating of “Buy” and an average target price of $24.83.

Stealth BioTherapeutics stock opened at $11.70 on Friday. Stealth BioTherapeutics has a 52 week low of $11.11 and a 52 week high of $20.99. The business’s 50-day moving average price is $12.49.

Stealth BioTherapeutics (NASDAQ:MITO) last released its earnings results on Wednesday, May 15th. The company reported ($0.12) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.26) by $0.14. Analysts expect that Stealth BioTherapeutics will post -0.18 EPS for the current fiscal year.

An institutional investor recently bought a new position in Stealth BioTherapeutics stock. Dean Capital Investments Management LLC purchased a new stake in Stealth BioTherapeutics Corp (NASDAQ:MITO) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 50,420 shares of the company’s stock, valued at approximately $646,000. Dean Capital Investments Management LLC owned 0.18% of Stealth BioTherapeutics at the end of the most recent quarter. 1.09% of the stock is currently owned by hedge funds and other institutional investors.

Stealth BioTherapeutics Company Profile

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.

Read More: What can cause a stock to outperform?

Analyst Recommendations for Stealth BioTherapeutics (NASDAQ:MITO)

Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with's FREE daily email newsletter.